Prediction of final tumor response to preoperative chemotherapy by Tc-99m MIBI imaging at the middle of chemotherapy in malignant bone and soft tissue tumors: Comparison with TI-201 imaging

Journal of Orthopaedic Research

Volumn 26, Issue 3, 2008, Pages 411-418

  Taki, Junichi ^a   Higuchi, Takahiro ^a   Sumiya, Hisashi ^a   Tsuchiya, Hiroyuki ^a   Minato, Hiroshi ^b   Tomita, Katsuro ^a   Tonami, Norihisa ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bone tumor; Preoperative chemotherapy; Soft tissue tumor; Tc 99m MIBI; TI 201

Indexed keywords

CAFFEINE; CISPLATIN; DOXORUBICIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; THALLIUM;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BONE CANCER; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CONTINUOUS INFUSION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SOFT TISSUE CANCER; TREATMENT RESPONSE; BONE TUMOR; CHILD; COMPARATIVE STUDY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PREOPERATIVE CARE; ROC CURVE; SCINTISCANNING; SOFT TISSUE TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; ROC CURVE; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; TECHNETIUM TC 99M SESTAMIBI; THALLIUM RADIOISOTOPES; TREATMENT OUTCOME;

EID: 40949158912     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20522     Document Type: Article

References (32)

1. Tsuchiya H, Tomita K, Minematsu K, et al. 1997. Limb salvage using distraction osteogenesis. A classification of the technique. J Bone Joint Surg [Br] 79:403-411.
2. Eilber FR, Morton DL, Eckardt J, et al. 1984. Limb salvage for skeletal and soft tissue sarcomas. Multidisciplinary preoperative therapy. Cancer 53:2579-2584.
3. Jaffe N, Patel SR, Benjamin RS. 1995. Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Hematol Oncol Clin North Am 9:825-840.
4. Tsuchiya H, Tomita K, Mori Y, et al. 1999. Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop Relat Res 358:27-35.
5. Caner B, Kitapcl M, Unlu M, et al. 1992. Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP. J Nucl Med 33:319-324.
6. Schillaci O, Buscombe JR. 2004. Breast scintigraphy today: indications and limitations. Eur J Nucl Med Mol Imaging 31 (Suppl 1):S35-S45.
7. Taki J, Sumiya H, Tsuchiya H, et al. 1997. Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy. J Nucl Med 38:501-506.
8. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities. Q J Nucl Med 47:51-57.
9. 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur J Nucl Med 24:511-515.
10. 99mTc-MIBI scintigraphy in the assessment of MDR1 over-expression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med 28: 1341-1350.
11. Taki J, Sumiya H, Asada N, et al. 1998. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med 39:1179-1184.
12. Sumiya H, Taki J, Tsuchiya H, et al. 1998. Midcourse thallium-201 scintigraphy to predict tumor response in bone and soft-tissue tumors. J Nucl Med 39:1600-1604.
13. 99mTc-macroaggregated albumin administration in patients with bone and soft-tissue tumors. J Nucl Med 43:1452-1456.
14. Metz CE. 1989. Some practical issues of experimental design and data analysis in radiological ROC studies. Invest Radiol 24:234-245.
15. Metz CE, Herman BA, Shen JH. 1998. Maximum likelihood estimation of receiver operating characteristic (ROC) curves from continuously-distributed data. Stat Med 17:1033-1053.
16. McNeil BJ, Keller E, Adelstein SJ. 1975. Primer on certain elements of medical decision making. N Engl J Med 293: 211-215.
17. Imbriaco M, Yeh SD, Yeung H, et al. 1997. Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. Cancer 80:1507-1512.
18. Kunisada T, Ozaki T, Kawai A, et al. 1999. Imaging assessment of the responses of osteosarcoma patients to preoperative chemotherapy: angiography compared with thallium-201 scintigraphy. Cancer 86:949-956.
19. Menendez LR, Fideler BM, Mirra J. 1993. Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy. J Bone Joint Surg [Am] 75:526-531.
20. Ohtomo K, Terui S, Yokoyama R, et al. 1996. Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma. J Nucl Med 37:1444-1448.
21. Caluser C, Macapinlac H, Healey J, et al. 1992. The relationship between thallium uptake, blood flow, and blood pool activity in bone and soft tissue tumors. Clin Nucl Med 17:565-572.
22. 201T1 uptake in tumors. Eur J Nucl Med 15:376-379.
23. Sessler MJ, Geck P, Maul FD, et al. 1986. New aspects of cellular thallium uptake: Tl+-Na+-2C1(-)-cotransport is the central mechanism of ion uptake. Nuklearmedizin 25:24-27.
24. Beanlands RS, Dawood F, Wen WH, et al. 1990. Are the kinetics of technetium-99m methoxyisobutyl isonitrile affected by cell metabolism and viability? Circulation 82:1802-1814.
25. Carvalho PA, Chiu ML, Kronauge JF, et al. 1992. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 33:1516-1522.
26. Piwnica WD, Kronauge JF, Chiu ML. 1990. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) techne-tium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 82:1826-1838.
27. Delmon-Moigeeon LI, Piwnica-Worms D, Van den Abbeele AD, et al. 1990. Uptake of the cation hexakis(2-methox-yisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 50:2198-2202.
28. Maublant JC, Zhang Z, Rapp M, et al. 1993. In vitro uptake of technetium-99m-teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m-sestamibi and thallium-201. J Nucl Med 34:1949-1952.
29. Bielack SS, Kempf-Bielack B, Delling G, et al. 2002. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790.
30. Hudson M, Jaffe MR, Jaffe N, et al. 1990. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 8:1988-1997.
31. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med 44:1394-1401.
32. Piwnica-Worms D, Chiu ML, Budding M, et al. 1993. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977-984.